all-import tavr segment deliv in-lin result
management continu point y/i share loss due price ew
share sequenti stabl posit revenu
ep outlook unchang though ep guidanc
lower street estim although management telegraph
expect revenu ep growth weight toward back
half weak start base may cast doubt compani abil
materi drive oper leverag cours year sinc
last review posit includ boston
scientif buy settlement although feel mani low-risk
procedur alreadi done low-risk approv addit
nonetheless flip side dont feel confid today
ew meet mitral guidanc recent abbott
neutral lawsuit vs pascal add wrinkl narr
remain posit centera ultra well ew breadth
mitral/tricuspid front balanc feel share fairli valu
account growth risk soft slow tavr growth
competit maintain neutral recommend
pascal trial updat import clinic updat
potenti pascal data present german societi
cardiolog meeting/dgk schedul later europcr
may enrol on-going clasp iid pursuant
dmr indic ew remain track commenc
enrol clasp iif fmr late clasp iif
continu await detail trial design
trim margin increas revenu forecast
slightli sh critic beat meaning lower
forecast margin push ep
valuat maintain neutral risk page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
adj ww thv revenu came conserv
forecast in-lin street estim compani longer
break vs ou tavr perform dollar manag estim
 tavr grew mid-teen in-lin market ou tavr
procedur improv low double-digit market growth
mid-teen procedur growth mirror last quarter perform
ew manag candid cede y/i share due price
competit note ew share stabl sequenti
adj gross margin model better gross margin
perform driven favor fx boost benefit
product mix even compani continu invest augment
manufactur capac exclud special adjust sg margin
consist last quarter y/i due higher invest
tavr therapi adopt initi partial off-set lower report
expens ou meanwhil adj margin fairli in-lin
estim adj ebit margin aggress
assumpt higher tax rate vs forecast hurt ep
sum adj ep model
revenu rais revenu estim slightli beat
structur heart critic leav tavr forecast unchang
actualsbtig estimate variancethv valv revenu heart valv revenu million adj consign revenu revenu expens expens net dilut gross margin bpssg margin bpsr spend bpsadj ebit margin bpstax rate bpssourc btig research estim compani filingsal metric present herein non-gaap basi margin estim non-gaap basi varianc
respect ep lift gross margin improv fx
headwind well better perform flip side assum
conserv sg margin reflect higher rate expens spend
adj ep forecast move
edward rate neutral feel ew current market capit
price lead market share fulli penetr matur tavr
market year feel share fairli valu btig
provid price target neutral-r stock risk rate includ
competit patent litig slippag product timelin chang
procedur reimburs futur devic data fda possibl
exhibit comp tabl larg cap med-tech compani
newnewold growth incom ep growth btig research estim compani filingsntm johnsonjnjnot bdxnot scientificbsxbuy lifesciencesewneutr factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/sal
edward incom revenu inc thv return y/i good gross sg other- total oper oper incom ex interest interest expens pre-tax incom tax non-gaap net non-gaap share ex marginsgross net total total total oper tax ep btig estim compani report
edward gaap revenu us y/i ou y/i heart y/i heart y/i y/i gaap net y/i non-gaap revenu us y/i ou y/i heart y/i heart y/i y/i non-gaap net y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
